Clinical Trial Update: Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating concurrent chemoradiation with durvalumab for locoregionally advanced nasopharyngeal carcinoma (NPC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: The University of Hong Kong | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN